千金药业品牌怎么样 申请店铺

我要投票 千金药业在女性洗液行业中的票数:125 更新时间:2025-01-22
千金药业是哪个国家的品牌?「千金药业」是 株洲千金药业股份有限公司 旗下著名品牌。该品牌发源于湖南省株洲市,由创始人江端预在1993年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
千金药业怎么样

株洲千金药业股份有限公司,前身为株洲市中药厂,1993年进行股份制改造,2004年上市(股票代码:600479),千金药业系国家大中型中药制药企业。旗下拥有十三家控股子公司。

千金药业注册资本3.05亿元,2013年底,总资产达到18.88亿元。经济效益综合指标在湖南省医药行业同行中排名第一,位居国内中药行业前列。

公司拥有国内最大、工艺最成熟的中药片剂生产线,日产量为1200万片,年产量可达35亿片。硬件装备先进,达到国内领先水平。2009年12月,位于河西天元区栗雨工业园的千金女性健康产业基地正式投产,该基地建设属国家高新技术产业项目,占地200亩达产规模30亿元。

公司专注于女性健康产业,已形成女性健康系列产品。公司现有片剂、颗粒剂、硬胶囊剂等八个剂型,十三条生产线,全部通过GMP认证。主要产品有:妇科千金片(胶囊)、补血益母颗粒、养阴清肺糖浆、千金椿乳凝胶、痛经宁糖浆(胶囊)、乳癖康胶囊妇科调经片、千金宁洗液、千金止带丸、八珍益母片、加味逍遥丸、乳泉颗粒等。

公司现有14个独家产品,近50个生产批文,拥有各项专利206件。其中主导产品妇科千金片(胶囊)是国家中药保护品种、国家基本药物,国家医保目录甲类品种,《中国药典》收载品种,国家秘密技术项目,是唯一列入国家秘密技术的妇科中成药品种。

千金药业及下属子公司现有员工4000余人,其中总部员工1800余人,大专以上学历人员超过52%,平均年龄为29岁,在职职业药师40余名。公司建立了近千人的专业化特质营销队伍,在全国除西藏、台湾、香港、澳门外的30多个省市设有联络处。

公司“十二五”战略目标是:成为女性健康领域标杆企业,成为中药衍生领域品牌产品;实现集团公司年销售收入达40亿元;实现员工收入增长翻番;使千金药业成为“快乐千金”、“和谐千金”、“富裕千金”和“品牌千金”。

发展历程

▲1966年:在株洲市徐家桥永安仁药店后,株洲千金药业股份有限公司的前身——株洲市中药加工厂(即株洲市医药公司星火中成药加工厂)成立。生产参苏丸、五积散等产品;注册商标为“火炬”。

▲1968年:更名为株洲市六二六制药厂,开始生产町水糖浆剂、丸剂和片剂。

▲1973年:六二六制药厂搬迁到金钩山路的原市委党校校址。

▲1975年:更名为株洲市中药制药厂。

▲1976年:启动“妇科千金片”研制。

▲1979年:注册使用“牡丹”商标;同年,妇科千金片获得生产批文并开始试生产。

▲1981年:被株洲市政府列为关、停、并、转的对象;同年,妇科千金片消毒灭菌技术攻关获得成功。

▲1983年:“妇科千金片”被评为湖南省优质产品。

▲1984年:牡丹牌“脑乐静”被评为湖南省优质产品。

▲1985年:“妇科千金片”被国家医药管理局评为优质产品。

▲1987年:更名为株洲市中药厂。

▲1991年:妇科千金片荣获国优银质奖。

▲1993年:改组为株洲千金药业股份有限公司;同年,妇科千金片销往新加坡。

▲1994年:妇科千金片入选国家基本药物。

▲1995年:“千金”牌商标获国家工商局注册商标证书。

▲1996年:“妇科千金片”被认定为1995年度湖南名牌产品。

▲1998年:成立陇西药材分公司。同年,湘江药业股份有限公司成立,千金药业投资816万元,占总股本的51%。同年,株洲千金医药贸易有限公司成立,注册资本500万元,千金药业和湘江药业分别投资480万元和20万元。

Zhuzhou Qianjin Pharmaceutical Co., Ltd., formerly Zhuzhou traditional Chinese medicine factory, was transformed into a joint-stock company in 1993 and listed in 2004 (Stock Code: 600479). Qianjin pharmaceutical is a large and medium-sized national traditional Chinese medicine pharmaceutical enterprise. It has 13 holding subsidiaries. Qianjin pharmaceutical has a registered capital of 305 million yuan, and by the end of 2013, its total assets reached 1888 million yuan. The comprehensive index of economic benefit ranks the first among the medical industry peers in Hunan Province, and ranks in the forefront of the domestic traditional Chinese medicine industry. The company has the largest and most mature production line of traditional Chinese medicine tablets in China, with a daily output of 12 million tablets and an annual output of 3.5 billion tablets. The hardware equipment is advanced, reaching the leading level in China. In December 2009, the Qianjin women's health industrial base, located in Liyu Industrial Park, Tianyuan District, Hexi, was officially put into operation. The construction of the base is a national high-tech industrial project, covering an area of 200 mu and reaching a production scale of 3 billion yuan. The company focuses on women's health industry and has formed a series of women's health products. The company has eight dosage forms such as tablet, granule, hard capsule and thirteen production lines, all of which have passed GMP certification. The main products are: gynecological Qianjin tablets (capsules), blood enriching mother granule, Yangyin Qingfei syrup, Qianjin Chun milk gel, dysmenorrhea syrup (capsule), Rupikang capsule, gynecological regulating menstruation tablets, Qianjin Ning lotion, Qianjin Zhibao pills, eight Zhen Yi Mu tablets, Jiawei Xiaoyao pills, and Ruquan granules. The company has 14 exclusive products, nearly 50 production approvals and 206 patents. Among them, the leading product Fukeqianjin tablet (capsule) is the national traditional Chinese medicine protection variety, the national basic drug, the category a variety in the national medical insurance catalog, the variety included in the Chinese Pharmacopoeia, and the national secret technology project. It is the only variety of Chinese traditional medicine for gynecology listed in the national secret technology. Qianjin Pharmaceutical Co., Ltd. and its subsidiaries have more than 4000 employees, including more than 1800 employees in the headquarters, more than 52% of them with college degree or above, with an average age of 29 and more than 40 on-the-job professional pharmacists. The company has established a professional marketing team of nearly one thousand people, with liaison offices in more than 30 provinces and cities except Tibet, Taiwan, Hong Kong and Macao. The company's "12th Five Year Plan" strategic goal is: to become a benchmark enterprise in the field of women's health and a brand product in the field of traditional Chinese medicine derivatives; to realize the annual sales revenue of the group company reaching 4 billion yuan; to realize the doubling of the income growth of employees; to make Qianjin pharmaceutical industry become "happy Qianjin", "harmonious Qianjin", "rich Qianjin" and "brand Qianjin". Development history ▲ 1966: after xujiaqiao yong'anren drugstore in Zhuzhou City, Zhuzhou Qianjin Pharmaceutical Co., Ltd., the predecessor of Zhuzhou traditional Chinese medicine processing factory (i.e. Xinghuo traditional Chinese medicine processing factory of Zhuzhou pharmaceutical company), was established. Production of Shensu pill, Wuji powder and other products; the registered trademark is "Torch". In 1968, it was renamed Zhuzhou 626 pharmaceutical factory and began to produce machishui syrup, pills and tablets. ▲ 1973: the 626 pharmaceutical factory was moved to the original site of the Party School of the municipal Party committee of jinyushan road. ▲ 1975: renamed Zhuzhou traditional Chinese medicine pharmaceutical factory. ▲ 1976: launch the development of "gynecology Qianjin tablet". In 1979, "Peony" trademark was registered and used; in the same year, gynecology Qianjin tablet obtained production approval and began trial production. In 1981, it was listed by Zhuzhou municipal government as the target of "close, stop, merge and transfer"; in the same year, the disinfection and sterilization technology of gynecology Qianjin tablet was successfully tackled. ▲ in 1983, "gynecology Qianjin tablet" was rated as high quality product of Hunan Province. ▲ 1984: Peony brand "Naolejing" was rated as high quality product of Hunan Province. In 1985, "gynecology Qianjin tablet" was rated as a high-quality product by the State Administration of medicine. ▲ 1987: renamed Zhuzhou traditional Chinese medicine factory. ▲ 1991: Gynecology Qianjin tablet won the national excellent silver medal. In 1993, it was reorganized into Zhuzhou Qianjin Pharmaceutical Co., Ltd. in the same year, Qianjin tablets for gynecology were sold to Singapore. ▲ 1994: Gynecology Qianjin tablet was selected as the national basic drug. ▲ in 1995, "Qianjin" brand trademark obtained the registered trademark certificate of the State Administration for Industry and commerce. In 1996, "gynecology Qianjin tablet" was recognized as the famous brand product of Hunan in 1995. ▲ 1998: Longxi herbal medicine branch was established. In the same year, Xiangjiang Pharmaceutical Co., Ltd. was established. Qianjin pharmaceutical invested 8.16 million yuan, accounting for 51% of the total share capital. In the same year, Zhuzhou Qianjin Pharmaceutical Trading Co., Ltd. was established with a registered capital of 5 million yuan. Qianjin pharmaceutical and Xiangjiang pharmaceutical invested 4.8 million yuan and 200000 yuan respectively.

本文链接: https://brand.waitui.com/db288be38.html 联系电话:800-878-8996

千城特选小程序码

7×24h 快讯

五大险企去年保费收入近3万亿,净利或超预期改善

随着全年保费收入陆续发布,上市险企2024年业绩可见端倪。从负债端看,中国人寿、中国人保、中国平安、中国太保、新华保险等A股五大上市险企去年共实现原保险保费收入2.8万亿元,同比增长5.3%;从资产端来看,去年9月以来资本市场回暖,也带动保险投资收益获得正增长。在“资负”共振之下,较早推动寿险改革和投资稳健的大型险企,有望交出一份不错的年度答卷。(证券时报)

2小时前

新加坡邮政任命Isaac Mah为集团首席财务官

根据新加坡交易所的一份文件,新加坡邮政任命Isaac Mah为集团首席财务官,自1月22日起生效。该公司已于12月披露了任命Mah担任首席财务官的意向。(界面)

2小时前

香港上市制度优化成果显现,“巨无霸”与“小而美”共舞

2024年下半年以来,港股IPO市场持续复苏,呈现出一派新气象:不仅有美的、顺丰等A股巨头纷纷赴港上市,也有地平线、黑芝麻智能、毛戈平等各领域的头部企业登陆港股市场。不难发现,港股生态正在发生一场巨变:除开前几年的阿里、京东、美团等“巨无霸”登陆港股市场外,一些“小而美”并在自身领域独树一帜的各类企业也纷纷涌入,港股市场正在成为消费和科技前沿企业的聚集地。分析人士指出,港股生态的这一场巨变是2018年以来香港上市制度不断优化、进化结出的硕果。(证券时报)

2小时前

Talpins的对冲基金向客户返还60亿美元,主要管理内部资本

Jeff Talpins的宏观交易对冲基金Element Capital Management去年返还了超过60亿美元资本,缩小了资产基础并向主要管理内部资金的方向迈进了一步。根据看到的一封致投资者信函,该公司在年底进行了第五次也是最后一次资本返还,将资产减至30亿美元。目前大约90%的资产是内部资金。此举是Element减少外部投资者计划的一部分。(新浪财经)

2小时前

消息称巴菲特旗下Pilot退出国际石油交易业务

三名消息人士周二表示,巴菲特旗下的Pilot Co.将关闭其国际石油交易业务,结束进军这一万亿美元规模的全球市场的计划,重新专注于其在美国的Pilot Flying J加油站和卡车驿站业务。据两名知情人士透露,作为巴菲特旗下伯克希尔哈撒韦公司的子公司,Pilot已经裁掉了几乎所有负责国际贸易的员工。他们表示,该公司将把资源用于发展自己的北美业务,而不是贸易。Pilot没有就该公司是否退出国际贸易业务置评。(新浪财经)

2小时前

本页详细列出关于西尼的品牌信息,含品牌所属公司介绍,西尼所处行业的品牌地位及优势。
咨询